INDEPENDENT STRATEGIC ADVISORY
For Pharma and MedTech teams facing complex access questions — and looking for a perspective that connects evidence to the decisions ahead.
THE WORK IN SHORT
Then read on to the defined engagements below — the video shows where each one sits.
Strategic support to connect unmet patient need, reimbursement requirements and the realities of individual markets.
An independent perspective on whether your evidence addresses the decisions that shape access — not simply whether it adds another analysis.
Focused conversations and workshops for teams navigating HEOR, European assessment developments and the role of AI.
ENGAGEMENT OPTIONS
Six defined engagements, each with a fixed scope, a clear deliverable and a price. Start with the smallest one that fits the decision in front of you — most teams grow into the next.
01 · Access Diagnostic
25.000DKK
1 market · 1 product · 2 weeks · ca. 18 hours
A fixed-scope review of one product in one market: where access breaks, which evidence actually moves the decision, and what to do next.
02 · Monthly advisory
18.000DKK / month
6 hours a month · minimum 3 months
A standing senior line for the decisions that do not wait for a project — for teams that own the work and want a second opinion on the hard ones.
03 · Evidence & submission review
from22.500DKK
1 dossier up to 80 pages · 10 working days · ca. 15 hours
An independent read of the evidence you are about to put in front of a payer, a committee or a board — before it goes out.
04 · Fractional project leadership
from60.000DKK / month
Ca. 40 hours a month · minimum 3 months
I take the lead on an access project end to end: the roadmap, the stakeholders, the governance and the roadblocks that need clearing.
05 · Custom template set
from25.000DKK
5 templates · ca. 15 hours · 3 weeks
The five templates from the complete pack, adapted to your portfolio, your market and the way your team writes submissions — so the decks carry your logic, not a generic one.
06 · Template membership
9.900DKK / year
12 months · team of up to 10
For teams facing the same questions year after year: current editions, new templates before anyone else sees them, and a quarterly session on what has changed in evidence and reimbursement.
07 · Evidence-to-Access Strategy Sprint
from45.000DKK
1 product · up to 3 markets · 3 weeks · ca. 32 hours
An intensive sprint that connects the clinical value of your product, the evidence you still need, what stakeholders prioritise and the practical requirements of the markets you are entering.
08 · International Market Prioritisation
from35.000DKK
6–8 markets · 3 weeks · ca. 25 hours
A structured answer to which markets you should enter first, and why — built on market attractiveness, reimbursement complexity, access to decision-makers, evidence requirements and competition.
ALSO AVAILABLE
For HEOR, market access and evidence teams who want a senior perspective on their own development — one conversation at a time.
3.000DKK
All prices in DKK, VAT included. Engagements outside Denmark add travel time and cost. Nothing is booked before we have talked — you describe the decision, I tell you honestly whether this is the right format for it.
Discuss which format fitsPOLICY, ADVOCACY & INDUSTRY COLLABORATION
Turning complex market access challenges into credible policy positions, collective action and meaningful change — drawing on experience with manifestos, white papers and industry alliances.
The product
How do we create access for a specific technology?
The organisation
How do we align companies, clinicians and other stakeholders around a shared goal?
The system
How do we formulate evidence-based recommendations that address barriers in the system itself?
From market barrier to policy change
For organisations whose access depends not only on their own product, but on structural conditions in the system.
You receive: A strategic advocacy plan with clear goals, documented arguments, prioritised stakeholders and next steps.
Evidence into influence
Not copywriting — analysis, strategic argument and evidence, written by someone who knows how access systems work.
You receive: A finished document with clear argument, documented sources, a defined position and usable recommendations.
From fragmented voices to collective action
Many structural challenges are bigger than one company. I help several actors find common ground around a well-defined goal.
You receive: A structured alliance with a clear purpose, a shared narrative and a plan for the work ahead.
Give a shared challenge a clear voice
A manifesto sets out a shared vision and core asks; a white paper goes deeper into evidence and reasoning. I facilitate the whole process — from defining the problem to validating a shared position.
You receive: A professionally written manifesto or joint statement, backed by clear argument and prioritised asks.
Bring the right stakeholders around the table
Roundtables, advisory sessions and stakeholder dialogues around a concrete market access challenge.
You receive: More than a well-run meeting — documented insights, areas of agreement, open questions and recommended actions.
HOW TO ENGAGE
01 · STRATEGY
from45.000DKK
1 policy issue · 4 weeks · ca. 30 hours
A focused analysis of the challenge, with a policy position, stakeholder strategy and action plan.
02 · CONTENT
from60.000DKK
1 paper · 6 weeks · ca. 40 hours
A white paper, position paper or manifesto with evidence, recommendations and a plan for use.
03 · COLLABORATION
from25.000DKK / month
Ca. 16 hours a month · minimum 6 months
A longer engagement to establish a shared agenda, allocate responsibility and build a coherent engagement strategy.
04 · FACILITATION
from30.000DKK
1 session · up to 15 participants · ca. 20 hours
A facilitated session on a concrete problem, with structured dialogue and a closing report.
I offer strategy, evidence-based policy work and facilitation — not guaranteed political outcomes. Examples from previous work are shared only where confidentiality allows.
Discuss a policy or alliance projectBEFORE YOU REACH OUT
With a short conversation about the decision you are facing. If I am not the right person for it, I will say so — and point you somewhere better.
The decision that matters, the evidence you already have, and access to the people who own the market. Everything else I can work with.
Diagnostic and review engagements usually start within two weeks. Longer engagements are planned around the one I am already running.
Yes. My own work has run across both — from global HEOR at Novo Nordisk to international market development in MedTech.
I have worked on access in Spain, the US, Canada, Poland, Brazil and South Africa. I work in the market you are facing, not a generic model.
Every engagement ends with something written you can act on — a roadmap, a read-out or a plan — plus a session where your team takes it over.
WORKING TOGETHER
A focused review, ongoing strategic sparring or a team workshop. We start with your access challenge and agree a scope that serves the decision — not the other way around.
LET’S ASK BETTER QUESTIONS